Universe Historical Balance Sheet

UPC Stock

USD 1.16 0.22 15.94%

Trend analysis of Universe Pharmaceuticals balance sheet accounts such as Total Assets of 47.2 M, Short Long Term Debt Total of 3.9 M, Other Current Liabilities of 3.2 M or Total Current Liabilities of 12.8 M provides information on Universe Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Universe Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Universe Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Universe Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Universe Pharmaceuticals is a good buy for the upcoming year.

Universe Pharmaceuticals Inventory

2.75 Million

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Universe Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.

About Universe Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Universe Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Universe Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Universe Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Universe currently owns. An asset can also be divided into two categories, current and non-current.

Universe Pharmaceuticals Balance Sheet Chart

At present, Universe Pharmaceuticals' Net Debt is projected to increase significantly based on the last few years of reporting. The current year's Retained Earnings is expected to grow to about 13.6 M, whereas Total Assets are forecasted to decline to about 47.2 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Accounts Payable Net Working Capital

Total Assets

Total assets refers to the total amount of Universe Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Universe Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Universe Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Universe Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Universe Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Universe Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Universe Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Universe Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Universe Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.At present, Universe Pharmaceuticals' Net Debt is projected to increase significantly based on the last few years of reporting. The current year's Retained Earnings is expected to grow to about 13.6 M, whereas Total Assets are forecasted to decline to about 47.2 M.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	3.9M	5.5M	6.3M	3.9M
Total Assets	59.5M	53.3M	61.3M	47.2M

Short Long Term Debt Total Total Assets

Universe Pharmaceuticals balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Long Term Investments	Property Plant And Equipment Gross	Short Long Term Debt
Total Assets		0.85	-0.57	-0.2	0.97	0.97	0.96	-0.34	0.42	0.83	0.88	0.21	0.98	0.93	0.98	0.93	-0.34	-0.65	-0.62	0.95	0.96	-0.2	0.97	-0.4	0.91	0.85
Short Long Term Debt Total	0.85		-0.58	-0.18	0.83	0.89	0.95	-0.44	0.65	0.59	0.88	-0.02	0.9	0.88	0.9	0.68	-0.44	-0.67	-0.6	0.74	0.93	-0.18	0.85	-0.61	0.96	1.0
Other Current Liab	-0.57	-0.58		0.89	-0.74	-0.73	-0.61	0.34	-0.33	-0.82	-0.45	-0.16	-0.62	-0.66	-0.65	-0.65	0.34	0.97	0.97	-0.66	-0.63	0.89	-0.74	0.43	-0.57	-0.58
Total Current Liabilities	-0.2	-0.18	0.89		-0.43	-0.4	-0.24	0.12	-0.12	-0.62	-0.01	-0.07	-0.27	-0.31	-0.29	-0.39	0.12	0.84	0.86	-0.36	-0.28	1.0	-0.42	0.19	-0.21	-0.18
Total Stockholder Equity	0.97	0.83	-0.74	-0.43		0.99	0.95	-0.34	0.42	0.92	0.81	0.21	0.97	0.94	0.98	0.95	-0.34	-0.81	-0.78	0.97	0.96	-0.43	1.0	-0.42	0.89	0.83
Net Tangible Assets	0.97	0.89	-0.73	-0.4	0.99		0.97	-0.33	0.46	0.88	0.85	0.17	0.98	0.94	0.99	0.92	-0.33	-0.8	-0.77	0.94	0.98	-0.4	1.0	-0.43	0.93	0.89
Property Plant And Equipment Net	0.96	0.95	-0.61	-0.24	0.95	0.97		-0.38	0.6	0.75	0.89	0.03	0.99	0.95	0.97	0.84	-0.38	-0.71	-0.65	0.89	1.0	-0.24	0.96	-0.51	0.98	0.95
Current Deferred Revenue	-0.34	-0.44	0.34	0.12	-0.34	-0.33	-0.38		-0.55	-0.28	-0.37	-0.11	-0.36	-0.59	-0.36	-0.33	1.0	0.36	0.36	-0.27	-0.36	0.12	-0.35	0.94	-0.38	-0.44
Net Debt	0.42	0.65	-0.33	-0.12	0.42	0.46	0.6	-0.55		0.14	0.4	-0.65	0.55	0.64	0.42	0.22	-0.55	-0.42	-0.35	0.35	0.59	-0.12	0.44	-0.76	0.65	0.65
Retained Earnings	0.83	0.59	-0.82	-0.62	0.92	0.88	0.75	-0.28	0.14		0.64	0.42	0.81	0.79	0.85	0.94	-0.28	-0.83	-0.84	0.91	0.77	-0.62	0.91	-0.26	0.65	0.59
Accounts Payable	0.88	0.88	-0.45	-0.01	0.81	0.85	0.89	-0.37	0.4	0.64		0.23	0.85	0.81	0.87	0.7	-0.37	-0.47	-0.41	0.83	0.84	-0.01	0.83	-0.4	0.81	0.88
Cash	0.21	-0.02	-0.16	-0.07	0.21	0.17	0.03	-0.11	-0.65	0.42	0.23		0.06	0.08	0.25	0.4	-0.11	-0.1	-0.17	0.22	0.02	-0.07	0.2	0.12	-0.05	-0.02
Non Current Assets Total	0.98	0.9	-0.62	-0.27	0.97	0.98	0.99	-0.36	0.55	0.81	0.85	0.06		0.96	0.98	0.89	-0.36	-0.72	-0.67	0.93	0.99	-0.27	0.98	-0.47	0.95	0.9
Other Assets	0.93	0.88	-0.66	-0.31	0.94	0.94	0.95	-0.59	0.64	0.79	0.81	0.08	0.96		0.94	0.87	-0.59	-0.75	-0.71	0.88	0.95	-0.31	0.94	-0.67	0.92	0.88
Cash And Short Term Investments	0.98	0.9	-0.65	-0.29	0.98	0.99	0.97	-0.36	0.42	0.85	0.87	0.25	0.98	0.94		0.93	-0.36	-0.74	-0.71	0.92	0.97	-0.29	0.98	-0.45	0.94	0.9
Net Receivables	0.93	0.68	-0.65	-0.39	0.95	0.92	0.84	-0.33	0.22	0.94	0.7	0.4	0.89	0.87	0.93		-0.33	-0.73	-0.75	0.92	0.86	-0.39	0.94	-0.34	0.78	0.68
Common Stock Total Equity	-0.34	-0.44	0.34	0.12	-0.34	-0.33	-0.38	1.0	-0.55	-0.28	-0.37	-0.11	-0.36	-0.59	-0.36	-0.33		0.36	0.36	-0.27	-0.36	0.12	-0.35	0.94	-0.38	-0.44
Common Stock Shares Outstanding	-0.65	-0.67	0.97	0.84	-0.81	-0.8	-0.71	0.36	-0.42	-0.83	-0.47	-0.1	-0.72	-0.75	-0.74	-0.73	0.36		0.99	-0.69	-0.74	0.84	-0.81	0.49	-0.7	-0.67
Inventory	-0.62	-0.6	0.97	0.86	-0.78	-0.77	-0.65	0.36	-0.35	-0.84	-0.41	-0.17	-0.67	-0.71	-0.71	-0.75	0.36	0.99		-0.67	-0.69	0.86	-0.78	0.47	-0.64	-0.6
Other Current Assets	0.95	0.74	-0.66	-0.36	0.97	0.94	0.89	-0.27	0.35	0.91	0.83	0.22	0.93	0.88	0.92	0.92	-0.27	-0.69	-0.67		0.89	-0.36	0.96	-0.29	0.79	0.74
Other Stockholder Equity	0.96	0.93	-0.63	-0.28	0.96	0.98	1.0	-0.36	0.59	0.77	0.84	0.02	0.99	0.95	0.97	0.86	-0.36	-0.74	-0.69	0.89		-0.28	0.96	-0.5	0.98	0.93
Total Liab	-0.2	-0.18	0.89	1.0	-0.43	-0.4	-0.24	0.12	-0.12	-0.62	-0.01	-0.07	-0.27	-0.31	-0.29	-0.39	0.12	0.84	0.86	-0.36	-0.28		-0.42	0.19	-0.21	-0.18
Net Invested Capital	0.97	0.85	-0.74	-0.42	1.0	1.0	0.96	-0.35	0.44	0.91	0.83	0.2	0.98	0.94	0.98	0.94	-0.35	-0.81	-0.78	0.96	0.96	-0.42		-0.43	0.9	0.85
Long Term Investments	-0.4	-0.61	0.43	0.19	-0.42	-0.43	-0.51	0.94	-0.76	-0.26	-0.4	0.12	-0.47	-0.67	-0.45	-0.34	0.94	0.49	0.47	-0.29	-0.5	0.19	-0.43		-0.57	-0.61
Property Plant And Equipment Gross	0.91	0.96	-0.57	-0.21	0.89	0.93	0.98	-0.38	0.65	0.65	0.81	-0.05	0.95	0.92	0.94	0.78	-0.38	-0.7	-0.64	0.79	0.98	-0.21	0.9	-0.57		0.96
Short Long Term Debt	0.85	1.0	-0.58	-0.18	0.83	0.89	0.95	-0.44	0.65	0.59	0.88	-0.02	0.9	0.88	0.9	0.68	-0.44	-0.67	-0.6	0.74	0.93	-0.18	0.85	-0.61	0.96

Click cells to compare fundamentals

Universe Pharmaceuticals Account Relationship Matchups

Universe Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	28.8M	70.1M	59.5M	53.3M	61.3M	47.2M
Short Long Term Debt Total	2.6M	4.3M	3.9M	5.5M	6.3M	3.9M
Other Current Liab	1.3M	464.0K	5.9M	3.3M	2.9M	3.2M
Total Current Liabilities	8.0M	11.2M	13.1M	13.8M	15.8M	12.8M
Total Stockholder Equity	20.8M	58.9M	46.4M	39.5M	45.5M	34.4M
Net Tangible Assets	12.2M	20.6M	58.8M	46.3M	53.2M	32.4M
Property Plant And Equipment Net	4.4M	15.4M	13.6M	15.0M	17.2M	10.6M
Net Debt	(7.4M)	(3.7M)	(1.8M)	197.2K	226.8K	238.1K
Retained Earnings	13.7M	25.1M	16.3M	10.2M	11.7M	13.6M
Accounts Payable	2.7M	5.3M	3.1M	4.6M	5.3M	3.8M
Cash	10.1M	8.1M	5.7M	5.3M	6.1M	7.1M
Non Current Assets Total	5.5M	19.7M	18.0M	16.5M	18.9M	13.1M
Other Assets	168.1K	186.5K	14.1M	12.9M	14.9M	15.6M
Cash And Short Term Investments	10.1M	21.8M	18.9M	18.5M	21.3M	14.4M
Net Receivables	10.9M	15.8M	15.2M	10.7M	12.3M	12.2M
Liabilities And Stockholders Equity	28.8M	70.1M	59.5M	53.3M	61.3M	47.2M
Inventory	1.9M	2.5M	2.2M	3.3M	3.0M	2.8M
Other Current Assets	443.7K	10.4M	5.3M	4.2M	4.9M	3.7M
Total Liab	8.0M	11.2M	13.1M	13.8M	15.8M	12.8M
Net Invested Capital	23.4M	63.3M	50.4M	45.0M	51.8M	38.4M
Long Term Investments	735K	744.9K	702.9K	685.3K	616.8K	572.9K
Property Plant And Equipment Gross	4.4M	15.4M	19.3M	21.0M	24.2M	12.8M
Short Long Term Debt	2.6M	4.3M	3.9M	5.5M	6.3M	3.9M
Total Current Assets	23.3M	50.5M	41.5M	36.8M	42.3M	34.1M
Accumulated Other Comprehensive Income	3.3M	4.5M	772.8K	26.3K	23.6K	22.5K
Net Working Capital	15.3M	39.3M	28.4M	23.1M	26.5M	21.3M
Short Term Debt	2.6M	4.3M	3.9M	5.5M	6.3M	3.9M
Intangible Assets	174.8K	178.5K	157.5K	148.6K	133.7K	135.3K
Property Plant Equipment	4.6M	4.4M	4.7M	4.3M	3.8M	3.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Universe Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Universe Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Universe Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Universe Pharmaceuticals Stock:

How To Invest In Universe

Details

Is Universe Stock a good investment?

Details

What is Universe Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.

You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Universe Pharmaceuticals. If investors know Universe will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Universe Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.82)

Earnings Share

(76.35)

Revenue Per Share

7.351

Quarterly Revenue Growth

(0.30)

Return On Assets

(0.06)

The market value of Universe Pharmaceuticals is measured differently than its book value, which is the value of Universe that is recorded on the company's balance sheet. Investors also form their own opinion of Universe Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Universe Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Universe Pharmaceuticals' market value can be influenced by many factors that don't directly affect Universe Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Universe Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Universe Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Universe Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Universe Historical Balance Sheet

Universe Pharmaceuticals Inventory

2.75 Million

About Universe Balance Sheet Analysis

Universe Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Accounts Payable

Universe Pharmaceuticals balance sheet Correlations

Universe Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Universe Pharmaceuticals balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Short Long Term Debt	+ 1.0	Short Long Term Debt Total
Total Liab	+ 1.0	Total Current Liabilities
Net Invested Capital	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Net Tangible Assets
Other Stockholder Equity	+ 1.0	Property Plant And Equipment Net
Common Stock Total Equity	+ 1.0	Current Deferred Revenue

Inventory	- 0.84	Retained Earnings
Common Stock Shares Outstanding	- 0.83	Retained Earnings
Retained Earnings	- 0.82	Other Current Liab
Net Invested Capital	- 0.81	Common Stock Shares Outstanding
Common Stock Shares Outstanding	- 0.81	Total Stockholder Equity
Common Stock Shares Outstanding	- 0.8	Net Tangible Assets